Miller Fisher Syndrome Associated With Immunotherapy for Metastatic Melanoma. (October 2018)

• Record Type: Journal Article
• Authors: Baird-Gunning, Jonathan J. D.; Weerasinghe, Dinushi; Silsby, Matthew; Gawarikar, Yash; Carlino, Matteo S.; Smith, Jessica L.; Vucic, Steve
• Is Part Of: Neurohospitalist. Volume 8:Number 4(2018)
• Page Start: 191
• Page End: 193
• Publication Date: 2018-10
• Subjects: Miller-Fisher syndrome -- immunotherapy -- melanoma -- CTLA-4 receptor -- PD-1 receptor; Nervous system -- Diseases -- Periodicals; Neurology -- Periodicals; 616.8
• DOI: 10.1177/1941874418778957
• Languages: English
• ISSNs: 1941-8744

Abstract

Immunotherapy is a treatment strategy that has demonstrated survival benefit for metastatic melanoma. Ipilimumab and nivolumab are examples of immunotherapy, in which monoclonal antibodies antagonize cytotoxic T-lymphocyte-associated protein 4 and programmed death-ligand 1 receptors, respectively, resulting in upregulation of the host immune response to cancer cells. There is increasing recognition of immune-mediated adverse events associated with immune therapies in patients with cancer. We present a case report of a patient who developed Miller Fisher syndrome associated with these therapies for metastatic melanoma along with a discussion of its management.